RÉSUMÉ
A rapid and convenient biochemometrics-based analysis of several cereal-derived extracts was used to identify n-alkyl(enyl)resorcinols (AR) as antifungals against Fusarium oxysporum. Total AR content and liquid chromatography/mass spectrometry (LC-MS)-based profiles were recorded for each extract, in addition to their antifungal activity, to help integrate these chemical and biological datasets by orthogonal partial least squares regression. In this study, we developed and used a micro-scale amended medium (MSAM) assay to evaluate the in vitro mycelial growth inhibition at low amounts of extracts. Triticale husk-derived extracts had the highest AR content (662.1 µg olivetol equivalent/g dry extract), exhibiting >79% inhibition at the highest doses (10.0â»1.0 µg/µL). Correlation of the chemical and antifungal datasets using supervised metabolite profiling revealed that 5-n-nonadecanylresorcinol, 5-n-heneicosylresorcinol, and 5-n-tricosyl-resorcinol were the most active ARs occurring in cereal products from Colombia. Hence, we propose the biochemometrics-based approach as a useful tool for identifying AR-like antifungals against F. oxysporum.
Sujet(s)
Antifongiques/métabolisme , Grains comestibles/métabolisme , Fusarium/effets des médicaments et des substances chimiques , Mycelium/effets des médicaments et des substances chimiques , Résorcinol/métabolisme , Antifongiques/composition chimique , Antifongiques/isolement et purification , Antifongiques/pharmacologie , Chromatographie en phase liquide/méthodes , Chromatographie en phase liquide/statistiques et données numériques , Grains comestibles/immunologie , Grains comestibles/microbiologie , Fusarium/croissance et développement , Humains , Méthode des moindres carrés , Métabolome/immunologie , Tests de sensibilité microbienne , Mycelium/croissance et développement , Maladies des plantes/immunologie , Maladies des plantes/microbiologie , Extraits de plantes/composition chimique , Résorcinol/composition chimique , Résorcinol/isolement et purification , Résorcinol/pharmacologie , Spectrométrie de masse en tandem/méthodes , Spectrométrie de masse en tandem/statistiques et données numériquesRÉSUMÉ
Tandem mass spectrometry (MS/MS) has made it possible to expand neonatal screening programs in different countries. This technology permits multiple and rapid diagnosis of diverse inborn errors of metabolism. However, its use in different programs around the world currently varies widely. There are different criteria for determining whether to include a specific disease in such programs, with some cases employing a more restrictive approach than others, based on the traditional screening principles enunciated by Wilson and Jungner, which will have to be reevaluated in light of this new technology. This article presents an update on the use of MS/MS in different regions of the world in terms of the diseases screened for, and the criteria for including new health problems in neonatal screening programs.
Sujet(s)
Erreurs innées du métabolisme/diagnostic , Dépistage néonatal/méthodes , Spectrométrie de masse en tandem , Amériques/épidémiologie , Asie/épidémiologie , Australie/épidémiologie , Europe/épidémiologie , Femelle , Humains , Nouveau-né , Mâle , Erreurs innées du métabolisme/épidémiologie , Dépistage néonatal/instrumentation , Dépistage néonatal/normes , Dépistage néonatal/statistiques et données numériques , Nouvelle-Zélande/épidémiologie , Spectrométrie de masse en tandem/méthodes , Spectrométrie de masse en tandem/statistiques et données numériquesRÉSUMÉ
La espectrometría de masas en tándem (MS/MS) ha posibilitado la expansión de los programas de tamizaje neonatal en diferentes países. Esta tecnología permite el diagnóstico múltiple y rápido de diversos errores innatos del metabolismo. Sin embargo, su aplicación en distintos programas en el ámbito mundial es actualmente muy heterogénea. Existen diferentes criterios para determinar si se incluye una enfermedad específica en esos programas, en algunos casos con un enfoque más restrictivo que en otros, de acuerdo con los principios tradicionales de tamizaje enunciados por Wilson y Jungner, los que habrán de ser reevaluados a la luz de esta nueva tecnología. En este trabajo se presenta una actualización sobre el uso de la MS/MS en diferentes regiones del mundo en relación con las enfermedades tamizadas y con los criterios de inclusión de nuevos problemas de salud en los programas de tamizaje neonatal.
Tandem mass spectrometry (MS/MS) has made it possible to expand neonatal screening programs in different countries. This technology permits multiple and rapid diagnosis of diverse inborn errors of metabolism. However, its use in different programs around the world currently varies widely. There are different criteria for determining whether to include a specific disease in such programs, with some cases employing a more restrictive approach than others, based on the traditional screening principles enunciated by Wilson and Jungner, which will have to be reevaluated in light of this new technology. This article presents an update on the use of MS/MS in different regions of the world in terms of the diseases screened for, and the criteria for including new health problems in neonatal screening programs.